Results 11 to 20 of about 38,272 (314)

Dapagliflozin: A Promising Strategy to Combat Cisplatin-Induced Hepatotoxicity in Wistar Rats

Biology
Recognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model.
Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Farook, Sofiya Khan, Anuradha Asokan Nair, Nirmal Nachiketh Binu, Mohamed Yehya, Mohammed Moin Khan   +8 more
doaj   +2 more sources

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

New England Journal of Medicine, 2022
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less.
S. Solomon, J. McMurray, B. Claggett, R. D. de Boer, D. DeMets, Adrian F. Hernandez, S. Inzucchi, M. Kosiborod, C. Lam, F. Martinez, Sanjiv J. Shah, Akshay S. Desai, P. Jhund, J. Bělohlávek, C. Chiang, C. Borleffs, J. Comín-Colet, D. Dobreanu, J. Drożdż, J. Fang, M. Alcocer-Gamba, Waleed Al habeeb, Yaling Han, Jose Walter Cabrera Honorio, S. Janssens, T. Katova, M. Kitakaze, B. Merkely, E. O’Meara, J. Saraiva, S. Tereshchenko, J. Thierer, M. Vaduganathan, O. Vardeny, S. Verma, V. Pham, U. Wilderäng, Natalia Zaozerska, E. Bachus, D. Lindholm, Magnus Petersson, A. Langkilde   +41 more
semanticscholar   +1 more source

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

Frontiers in Pharmacology, 2021
As a newly approved oral hypoglycaemic agent, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which is derived from the natural product phlorizin can effectively reduce blood glucose.
Liuran Li, Qinghua Li, Wenbin Huang, Yibing Han, Huiting Tan, Min An, Qianru Xiang, Rui Zhou, Li Yang, Li Yang, Yanzhen Cheng   +10 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source

Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]

, 2018
In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A, Baldi I, Bottigliengo D, Consoli A, DARWIN-T2D network., Fadini GP, Giaccari A, Sesti G, Zatti G   +8 more
core   +2 more sources

Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished.
Hilmi Alnsasra, Hilmi Alnsasra, Gal Tsaban, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Abed N. Azab, Joseph Azuri, Joseph Azuri, Ariel Hammerman, Ronen Arbel   +12 more
doaj   +1 more source

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [PDF]

, 2017
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure.
De Vecchis, Ferrannini, Fitchett, Francis, Greenberg, Hammon, Heise, Heise, Hirose, Lindner, Neal, Peacock, Rabe, Schmieder, Schneider, Schrier, Schrier, Shimizu, Titze, Titze, Titze, Weinfeld, Zinman   +22 more
core   +1 more source

Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. [PDF]

, 2016
Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion coupling in pancreatic A-cells is believed to be an important factor during development of diabetes.
Ahlstedt, I., Elhachmane, M., Gopel, S., Pedersen, MORTEN GRAM   +3 more
core   +1 more source

Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Frontiers in Pharmacology, 2023
Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R).
Weixia Chen, Yue Zhang, Zuoxiang Wang, Ming-yue Tan, Jia Lin, Xiao-shun Qian, Hongxia Li, Tingbo Jiang   +7 more
semanticscholar   +1 more source

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [PDF]

, 2012
Background Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends
Clar, C., Court, Rachel A., Gill, J. A. (James Alexander), Waugh, Norman   +3 more
core   +1 more source